Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATG dose comparison in conditioning for haploidentical HSCT without in vitro T-cell depletion
ChiCTR-TRC-11001761Phase 4Completed
- Sponsor
- Peking University People's Hospital
- Start
- Jan 2010
- Modality
- Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of antithymocyte globulin in hematopoietic malignancies (2 arms), sponsored by Peking University People's Hospital. Primary endpoint: acute graft-versus-host disease. Started Jan 2010; status: completed.
02
Drugs
antithymocyte globulin
03
Conditions
hematopoietic malignancies
Beyond the preview
Go deeper on ChiCTR-TRC-11001761.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-TRC-11001761.